A Study To Compare the Effect of Vildagliptin Compared to Placebo in Patients With Type 2 Diabetes

A Multicenter, Double-Blind, Randomized, Parallel-Group Study to Compare the Effect of 12 Weeks Treatment With Vildagliptin (50mg qd, 50mg Bid, 100mg qd) to Placebo in Patients With Type 2 Diabetes

This study is not being conducted in the United States. Vildagliptin is an oral antidiabetic agent. This 12-week clinical study is to evaluate the effect of vildagliptin 50mg qd, 50mg bid or 100mg qd compared to placebo in patients with type 2 diabetes.

Inclusion Criteria:

• Diagnosis of type 2 diabetes
• Patients who have been placed on dietary therapy/exercise therapy without achievement of glycemic control
• Outpatients

Exclusion Criteria:

• Type 1 diabetes, diabetes that is a result of pancreatic injury, or secondary forms of diabetes
• Significant cardiovascular disease
• Significant diabetic complications

Other protocol-defined inclusion/exclusion criteria may apply